Here are the 424B prospectus supplements from Zura Bio Limited (ZURA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ZURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZURA filings page.
Zura Bio Limited is offering 18,200,000 Class A ordinary shares and pre-funded warrants to purchase 1,800,000 Class A ordinary shares. The offering is being made at a public price of $6.25 per Class A ordinary share and $6.249 per pre-funded warrant, with expected delivery on or about February 26, 2026.
The prospectus supplement states net proceeds to the company of approximately $117.0 million before expenses (or approximately $134.6 million if the underwriters fully exercise a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares). The company also discloses preliminary cash and cash equivalents of approximately $109.4 million as of December 31, 2025, subject to audit. The pre-funded warrants have a nominal exercise price of $0.001, do not expire, and include ownership limitations up to 9.99% (adjustable up to 19.99% with notice).
Zura Bio Limited is offering Class A ordinary shares and pre-funded warrants in a primary registered offering (preliminary prospectus supplement dated ). The pre-funded warrants have an exercise price of $0.001 and do not expire; they are exercisable subject to ownership limits (default 9.99%, adjustable to 19.99% with notice).
The company’s Class A ordinary shares trade on Nasdaq under “ZURA”; the last reported sale price on February 23, 2026 was $6.53. The prospectus discloses a preliminary cash and cash equivalents estimate of $109.4 million as of December 31, 2025 (unaudited). The share count basis used is 65,018,058 Class A ordinary shares outstanding as of September 30, 2025.
Proceeds are intended for working capital, advancing the pipeline and general corporate purposes. The offering is subject to completion of terms, underwriting arrangements, and customary conditions; information on offering size, price per share and aggregate proceeds is omitted in the provided excerpt.